Plasminogen Activator Inhibitor Type 1 Gene Polymorphism and Sepsis

Plasminogen activator inhibitor type 1 (PAI-1) is a 50-kilodalton glycoprotein of the serine protease inhibitor family. The primary role of PAI-1 in vivo is the inhibition of both tissue- and urokinase-type plasminogen activators. In addition to this function, PAI-1 acts as an acute-phase protein du...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2005-11, Vol.41 (Supplement-7), p.S453-S458
Main Authors: Hermans, P. W. M., Hazelzet, Jan A.
Format: Article
Language:English
Subjects:
Bacterial diseases
Bacterial sepsis
Biological and medical sciences
Clinical Trials as Topic
Coagulation
Drug Delivery Systems
Fibrinolysis
Gene Expression Regulation
Genes
Genotypes
Glycoproteins
Health outcomes
Human bacterial diseases
Humans
Infectious diseases
Inflammation
Inflammation - genetics
Inflammation - immunology
Medical sciences
Meningococcal Infections - genetics
Meningococcal Infections - immunology
Mucocutaneous lymph node syndrome
Neisseria meningitidis
Plasminogen Activator Inhibitor 1 - biosynthesis
Plasminogen Activator Inhibitor 1 - genetics
Plasminogen Activator Inhibitor 1 - immunology
Plasminogen activators
Plasminogen inactivators
Polymorphism
Polymorphism, Genetic
Protease inhibitors
Sepsis
Sepsis - etiology
Sepsis - genetics
Sepsis - immunology
Septic shock
Severity of Illness Index
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Plasminogen activator inhibitor type 1 (PAI-1) is a 50-kilodalton glycoprotein of the serine protease inhibitor family. The primary role of PAI-1 in vivo is the inhibition of both tissue- and urokinase-type plasminogen activators. In addition to this function, PAI-1 acts as an acute-phase protein during acute inflammation. PAI-1 is a pivotal player in the pathogenesis of sepsis, a complex clinical syndrome that results from a systemic inflammatory response. In patients with sepsis, the levels of PAI-1 are positively related to poor outcome, increased severity of disease, and increased levels of various cytokines, acute-phase proteins, and coagulation parameters. The 4G/5G insertion/deletion promoter polymorphism, which leads to differences in PAI-1 production, has been demonstrated to affect the risk of developing severe complications and dying from sepsis during meningococcal infection and multiple trauma.
ISSN:1058-4838
1537-6591
DOI:10.1086/431996